Stocktoria
Lipocine Inc. LPCN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-21
Lipocine Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $11.2M | -$2.9M | $500,000 | $16.1M |
| R&D expense | $8.6M | $7.4M | $10.2M | $8.6M | $7.7M |
| Operating income | -$10.4M | -$1.2M | -$17.9M | -$12.1M | $3.1M |
| Interest expense | — | — | — | $27,098 | $203,292 |
| Income tax | $200 | $681 | $755 | $681 | $200 |
| Net income | -$9.6M | $8,352 | -$16.4M | -$10.8M | -$634,399 |
| EPS (diluted) | $-1.69 | — | $-3.14 | $-2.15 | $-0.01 |
| Operating cash flow | -$9.8M | -$1.2M | -$11.9M | -$12.0M | -$4.4M |
| Free cash flow | — | -$1.3M | -$11.9M | -$12.1M | -$4.4M |
| Cash & equivalents | $5.2M | $6.2M | $4.8M | $3.1M | $3.0M |
| Total assets | $17.0M | $22.5M | $23.0M | $37.5M | $52.5M |
| Total liabilities | $2.5M | $1.5M | $2.6M | $1.9M | $6.9M |
| Shareholders' equity | $14.5M | $21.0M | $20.4M | $35.6M | $45.6M |
Source: SEC EDGAR filings · CIK 0001535955 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.